Category: Achilles Therapeutics

UK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financing

Achilles Therapeutics, BIA, Biotech, Centessa, Clarivate, exscientia, Gyroscope, Life Sciences, News, Oxford Nanopore, R&D, UK, Vaccitech / July 6, 2021 July 6, 2021

The UK’s biotechnology sector is going through a purple patch, attracting almost £1.6 billion ($2.2 billion) in financing in the three months to end-May – which is a record for the industry. The new figures – from the BioIndustry Association and Clarivate – were dominated by more than £1 billion in venture capital funding for …

UK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financing Read More »

Cancer Research UK spinout Achilles raises $175.5m in IPO

Achilles Therapeutics, Biotech, cell therapy, Immuno-Oncology, IPO, News, Oncology, UK / April 8, 2021 April 8, 2021

UK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that will be used to take its personalised T cell therapy for lung and skin cancers through proof-of-concept trials. The new funding will also be used to advance two more T cell programmes for head and neck and …

Cancer Research UK spinout Achilles raises $175.5m in IPO Read More »

Achilles Therapeutics’ IPO nabs $175M to bring cell therapies to solid tumors

Achilles Therapeutics, BioPharma, biopharma nl, biotech IPO, cancer immunotherapy, Clinical Trials, Daily, London, Pharma, SYN, Top Story, tumor-infiltrating lymphocyte / March 31, 2021 March 31, 2021

The Achilles Therapeutics IPO comes as several other biotechs make progress developing a type of cancer immunotherapy called a tumor-infiltrating lymphocyte. Clinical-stage Achilles contends its approach could best them all.